286 related articles for article (PubMed ID: 36413882)
1. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract][Full Text] [Related]
2. The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China.
Cheng R; Zhou Z; Liu Q
Adv Ther; 2023 Oct; 40(10):4298-4309. PubMed ID: 37453992
[TBL] [Abstract][Full Text] [Related]
3. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.
Li W; Wan L
Front Public Health; 2022; 10():1015702. PubMed ID: 36408023
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer.
Zheng Z; Zhu H; Fang L; Cai H
Front Pharmacol; 2022; 13():996914. PubMed ID: 36172187
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.
Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract][Full Text] [Related]
10. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
11. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
Huo G; Liu W; Kang S; Chen P
Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
[No Abstract] [Full Text] [Related]
12. Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China.
Wang H; Liao L; Xu Y; Long Y; Wang Y; Zhou Y
Front Oncol; 2022; 12():1081750. PubMed ID: 36582798
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
14. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China.
Li W; Wan L
PLoS One; 2023; 18(6):e0286595. PubMed ID: 37262075
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China.
Zheng Z; Zhu G; Cao X; Cai H; Zhu H
Expert Rev Clin Pharmacol; 2023 Mar; 16(3):267-273. PubMed ID: 36877089
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Zhao M; Shao T; Chi Z; Tang W
Front Public Health; 2023; 11():1051484. PubMed ID: 36908446
[TBL] [Abstract][Full Text] [Related]
18. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Zhou C; Wang Z; Sun M; Cao L; Ma Z; Wu R; Yu Y; Yao W; Sun S; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Hu C; Liu J; Liu Y; Wang M; Li X; Sun P; Shu Y; Zhou J; Li J; Gu K; Wang C; Zhao H; Zhang Y; Liu C; Wang J; Chen R; Qin M; Wang H; Yang J
Nat Cancer; 2023 Jun; 4(6):860-871. PubMed ID: 37322367
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China.
Shang F; Zhang B; Kang S
Expert Rev Pharmacoecon Outcomes Res; 2023 Mar; 23(3):337-343. PubMed ID: 36655382
[TBL] [Abstract][Full Text] [Related]
20. Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.
Shi Y; Qian D; Li Y; Chen W; Bo M; Zhang M; Shi J; Jia B; Dai Y; Li G
Transl Cancer Res; 2023 Apr; 12(4):928-938. PubMed ID: 37180653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]